J P Morgan Chase & Co Cuts Vectura Group PLC (VEC) Price Target to GBX 210

Vectura Group PLC (LON:VEC) had its price objective decreased by equities researchers at J P Morgan Chase & Co from GBX 240 ($3.04) to GBX 210 ($2.66) in a report released on Friday, May 12th. The firm currently has an “overweight” rating on the stock. J P Morgan Chase & Co’s price target points to a potential upside of 86.17% from the stock’s previous close.

VEC has been the topic of a number of other research reports. Numis Securities Ltd reaffirmed a “buy” rating and set a GBX 225 ($2.85) target price on shares of Vectura Group PLC in a report on Friday, March 17th. Peel Hunt reiterated a “buy” rating and set a GBX 200 ($2.53) price target on shares of Vectura Group PLC in a research report on Friday, February 24th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 225 ($2.85) price target on shares of Vectura Group PLC in a research report on Tuesday, January 24th. Finally, Citigroup Inc. reiterated a “buy” rating and set a GBX 225 ($2.85) price target on shares of Vectura Group PLC in a research report on Thursday, March 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of GBX 210.13 ($2.66).

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Shares of Vectura Group PLC (LON VEC) opened at 112.80 on Friday. The company has a 50 day moving average price of GBX 124.51 and a 200 day moving average price of GBX 138.92. The company’s market capitalization is GBX 764.39 million. Vectura Group PLC has a 12-month low of GBX 110.17 and a 12-month high of GBX 166.97.

COPYRIGHT VIOLATION WARNING: This article was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.com-unik.info/2017/06/17/vectura-group-plc-vec-pt-lowered-to-gbx-210-at-jpmorgan-chase-co-updated-updated-updated.html.

Vectura Group PLC Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

What are top analysts saying about Vectura Group PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vectura Group PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit